Is Bio-Rad’s Earnings Miss and Biodesix Partnership Redefining the Investment Outlook for BIO?

On October 29, 2025, Bio-Rad Laboratories reported third-quarter earnings with sales of US$653 million and a net loss of US$341.9 million, while also completing a major share repurchase and announcing an expanded oncology diagnostics partnership with Biodesix utilizing its Droplet Digital PCR technology. This combination of financial resilience amid challenging market conditions and continued investment in advanced molecular diagnostics positions Bio-Rad at the forefront of precision medicine innovation. We'll examine how Bio-Rad's sustained focus on digital PCR and strategic partnerships could impact its investment narrative and future growth.

Uncover the next big thing with financially sound penny stocks that balance risk and reward.

Bio-Rad Laboratories Investment Narrative Recap

To hold Bio-Rad Laboratories stock, investors need to believe in the company's ability to maintain its momentum in advanced molecular diagnostics, especially as the life sciences and diagnostics markets face tight funding and reimbursement pressures. The recent third-quarter update, with flat sales and a significant net loss, does little to alter the immediate focus on recovering gross margins and reigniting growth in core instrument demand, so the short-term catalyst remains tied to a turnaround in key end markets, while the biggest risk continues to be ongoing softness in academic and biotech funding.

The expanded oncology diagnostics partnership with Biodesix, leveraging Bio-Rad's Droplet Digital PCR technology, stands out as a recent announcement that aligns closely with efforts to strengthen the ddPCR segment, a growth driver that could counterbalance otherwise slow revenue progress if successfully executed amid market headwinds.

Yet, despite resilient efforts, investors should be aware that ongoing softness in academic and global biotech funding could still...

Read the full narrative on Bio-Rad Laboratories (it's free!)

Bio-Rad Laboratories' outlook anticipates $2.7 billion in revenue and $232.0 million in earnings by 2028. This reflects an annual revenue growth rate of 2.3% and a $87.2 million earnings decrease from the current earnings of $319.2 million.

Uncover how Bio-Rad Laboratories' forecasts yield a $324.00 fair value, in line with its current price.

Exploring Other PerspectivesBIO Community Fair Values as at Nov 2025

Simply Wall St Community members provided two fair value estimates for Bio-Rad Laboratories, ranging from US$324 to US$423.41 per share. Many are watching for a recovery in demand from academic and biotech customers, which remains a key factor for future performance and is at the center of ongoing debate among market participants.

Story Continues

Explore 2 other fair value estimates on Bio-Rad Laboratories - why the stock might be worth just $324.00!

Build Your Own Bio-Rad Laboratories Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

A great starting point for your Bio-Rad Laboratories research is our analysis highlighting 3 key rewards that could impact your investment decision. Our free Bio-Rad Laboratories research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Bio-Rad Laboratories' overall financial health at a glance.

Looking For Alternative Opportunities?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

Find companies with promising cash flow potential yet trading below their fair value. The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 27 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement. Explore 28 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include BIO.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments